Page 10 - CIRN Annual Report 2017

immunogenicity in 108 participants; follow-up will be completed in 2017.
The Pharmacists as Immunizers study is a prospective CTN study of
on vaccine coverage, compared to control communities, measured
was not common and AEFI did not interfere with study completion
In preparation for expected clinical studies of a vaccine to prevent
the effectiveness of targeted patient interventions by pharmacists
began in November 2016 and focuses on communities in NS and
vaccine reports, and vaccine doses delivered. This 2-year study
highest after the first (unblinded) dose. Systemic muscle aches,
(120/121 participants completed the immunizations). Complete
drowsiness and nausea were common after both doses. Fever
using de-identified pharmacy database information, physician
A phase 1 study of a novel CMV vaccine is testing safety and
immunogenicity results are expected in early 2017.

invasive Haemophilus influenzae type a (Hia) disease in Indigenous communities, we initiated studies to determine burden of disease, Hia immunoepidemiology, and knowledge, attitudes, beliefs, and behaviors about Hia disease among Indigenous communities in Northern Ontario. Engagement with Indigenous communities is a central focus of this work. The study is just beginning work

New Brunswick.

Clinical Trials Network (CTN)

questions in large and specialized groups with a focus on safety,
sites in Vancouver, Calgary, Hamilton, Toronto, Ottawa, Sudbury,
The Clinical Trials Network (CTN) is able to conduct rapid
immunogenicity, and mechanisms of immunity. CTN includes
clinical trials to address public health-relevant immunization

Montreal, Quebec City, and Halifax. The network completed a rapid Phase I study of the VSV-EBOV Ebola vaccine at the Halifax site in 2015-16, following an expedited grant application and review process during the Ebola outbreak. This phase 1 study was completed in <6 weeks, demonstrating CTN’s strong rapid research response capacity. A second study assessed the need for a Hepatitis B booster dose in adolescence for jurisdictions with in